Naturally occurring bacteriophages lyse a large proportion of canine and feline uropathogenic Escherichia coli isolates in vitro

Research in Veterinary Science

Volumn 85, Issue 1, 2008, Pages 1-7

  Freitag, T ^a   Squires, R A ^a   Schmid, J ^a  

^a MASSEY UNIVERSITY   (New Zealand)

Author keywords

Bacteriophage therapy; Cat; Dog; Escherichia coli; Urinary tract infection; Uropathogenic

Indexed keywords

DNA FRAGMENT;

ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE T4; BACTERIUM ISOLATE; CAT DISEASE; DNA SEQUENCE; DOG DISEASE; ELECTRON MICROSCOPY; FEASIBILITY STUDY; FECES ANALYSIS; IN VITRO STUDY; LYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; URINARY TRACT INFECTION; UROPATHOGENIC ESCHERICHIA COLI; VIROTHERAPY;

ANIMALS; BACTERIOPHAGES; CAT DISEASES; CATS; DOG DISEASES; DOGS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; PHYLOGENY; URINARY TRACT INFECTIONS;

CANIS FAMILIARIS; ESCHERICHIA COLI; FELIDAE;

EID: 43649104236     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2007.09.004     Document Type: Article

References (53)

1. Abe M., Izumoji Y., and Tanji Y. Phenotypic transformation including host-range transition through superinfection of T-even phages. FEMS Microbiol. Lett. 269 (2007) 145-152
2. Ackermann H.W., and DuBow M.S. Viruses of Prokaryotes. Volume I. General Properties of Bacteriophages (1987), CRC Press, Boca Raton, FL
3. Ackermann H.W., and Eisenstark A. The present state of phage taxonomy. Intervirology 3 (1974) 201-219
4. Alisky J., Iczkowski K., Rapoport A., and Troitsky N. Bacteriophages show promise as antimicrobial agents. J. Infect. 36 (1998) 5-15
5. Barrow P., Lovell M., and Berchieri Jr. A. Use of lytic bacteriophage for control of experimental Escherichia coli septicemia and meningitis in chickens and calves. Clin. Diagn. Lab. Immunol. 5 (1998) 294-298
6. Bartges J.W. Urinary tract infections. In: Ettinger S.J., and Feldman E.C. (Eds). Textbook of Veterinary Internal Medicine (2005), Elsevier Saunders, St. Louis, Missouri 1800-1808
7. Birge E.A. Bacterial and Bacteriophage Genetics. fourth ed. (2000), Springer-Verlag, New York
8. Biswas B., Adhya S., Washart P., Paul B., Trostel A.N., Powell B., Carlton R., and Merril C.R. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70 (2002) 204-210
9. Boyd E.F., and Brussow H. Common themes among bacteriophage-encoded virulence factors and diversity among the bacteriophages involved. Trends Microbiol. 10 (2002) 521-529
10. Bruttin A., and Brussow H. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob. Agents Chemother. 49 (2005) 2874-2878
11. Büchen-Osmond, C., 2006. ICTVdB - The Universal Virus Database. In Büchen-Osmond, C.E. (Ed.), ICTVdB - The Universal Virus Database, Version 4 (New York, USA, ICTVdB Management, Mailman School of Public Health, Columbia University, New York, NY, USA).
12. Chenna R., Sugawara H., Koike T., Lopez R., Gibson T.J., Higgins D.G., and Thompson J.D. Multiple sequence alignment with the Clustal series of programs. Nucl. Acids Res. 31 (2003) 3497-3500
13. Chibani-Chennoufi S., Sidoti J., Bruttin A., Kutter E., Sarker S., and Brussow H. In vitro and in vivo bacteriolytic activities of Escherichia coli phages: implications for phage therapy. Antimicrob. Agents Chemother. 48 (2004) 2558-2569
14. Cohn L.A., Gary A.T., Fales W.H., and Madsen R.W. Trends in fluoroquinolone resistance of bacteria isolated from canine urinary tracts. J. Vet. Diagn. Invest. 15 (2003) 338-343
15. Comer K.M., and Ling G.V. Results of urinalysis and bacterial culture of canine urine obtained by antepubic cystocentesis, catheterization, and the midstream voided methods. J. Am. Vet. Med. Assoc. 179 (1981) 891-895
16. Dawson B., and Trapp R. Basic and Clinical Biostatistics. second ed. (1994), Appleton and Lange, Norwalk, CT, USA
17. Drazenovich N., Ling G.V., and Foley J. Molecular investigation of Escherichia coli strains associated with apparently persistent urinary tract infection in dogs. J. Vet. Intern. Med. 18 (2004) 301-306
18. Drulis-Kawa Z., Weber-Dabrowska B., Lewczyk E., Jankowski S., and Doroszkiewicz W. The sensitivity of the uropathogenic Escherichia coli strains to antibiotics, bacteriophages and bactericidal serum activity. Pol. Merkuriusz Lek. 13 (2002) 470-472 (in Polish)
19. Dubos R.J., Straus J.H., and Pierce C. The multiplication of bacteriophage in vivo and its protective effect against an experimental infection with Shigella dysenteriae. J. Exp. Med. 78 (1943) 161-168
20. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am. J. Med. 113 Suppl. 1A (2002) 5S-13S
21. Freitag T., Squires R.A., Schmid J., and Elliott J. Feline uropathogenic Escherichia coli from Great Britain and New Zealand have dissimilar virulence factor genotypes. Vet. Microbiol. 106 (2005) 79-86
22. Freitag T., Squires R.A., Schmid J., Elliott J., and Rycroft A.N. Antibiotic sensitivity profiles do not reliably distinguish relapsing or persisting infections from reinfections in cats with chronic renal failure and multiple diagnoses of Escherichia coli urinary tract infection. J. Vet. Intern. Med. 20 (2006) 245-249
23. Geier M.R., Trigg M.E., and Merril C.R. Fate of bacteriophage lambda in non-immune germ-free mice. Nature 246 (1973) 221-223
24. Huff W.E., Huff G.R., Rath N.C., Balog J.M., and Donoghue A.M. Bacteriophage treatment of a severe Escherichia coli respiratory infection in broiler chickens. Avian Dis. 47 (2003) 1399-1405
25. Huff W.E., Huff G.R., Rath N.C., Balog J.M., and Donoghue A.M. Therapeutic efficacy of bacteriophage and Baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers. Poult. Sci. 83 (2004) 1944-1947
26. Johnson J.R., Kaster N., Kuskowski M.A., and Ling G.V. Identification of urovirulence traits in Escherichia coli by comparison of urinary and rectal E. coli isolates from dogs with urinary tract infection. J. Clin. Microbiol. 41 (2003) 337-345
27. Johnson J.R., and Russo T.A. Extraintestinal pathogenic Escherichia coli: "the other bad E. coli". J. Lab. Clin. Med. 139 (2002) 155-162
28. Kutter E., Gachechiladze K., Poglazov A., Marusich E., Shneider M., Aronsson P., Napuli A., Porter D., and Mesyanzhinov V. Evolution of T4-related phages. Virus Genes 11 (1995) 285-297
29. Kutter E., Raya R., and Carlson K. Molecular mechanisms of phage infection. In: Kutter E., and Sulakvelidze A. (Eds). Bacteriophage As Antibiotics: Molecular Biology and Applications (2005), CRC Press, Boca Raton, FL 165-213
30. Kutter E., and Sulakvelidze A. Bacteriophage as Antibiotics: Molecular Biology and Applications (2005), CRC Press, Boca Raton, FL
31. Ling G.V. Bacterial infections of the urinary tract. In: Ettinger S.J., and Feldman E.C. (Eds). Textbook of Veterinary Internal Medicine (2000), W.B. Saunders, Philadelphia, PA 1678-1686
32. Ludbrook J. Multiple comparison procedures updated. Clin. Exp. Pharmacol. Physiol. 25 (1998) 1032-1037
33. Lwoff A. Lysogeny. Bacteriol. Rev. 17 (1953) 269-337
34. Manges A.R., Johnson J.R., Foxman B., O'Bryan T.T., Fullerton K.E., and Riley L.W. Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group. N. Engl. J. Med. 345 (2001) 1007-1013
35. Mulvey M.A., Schilling J.D., and Hultgren S.J. Establishment of a persistent Escherichia coli reservoir during the acute phase of a bladder infection. Infect. Immun. 69 (2001) 4572-4579
36. Perepanova, T.S., Darbeeva, O.S., Kotliarova, G.A., Kondrat'eva, E.M., Maiskaia, L.M., Malysheva, V.F., Baiguzina, F.A., Grishkova, N.V., 1995, The efficacy of bacteriophage preparations in treating inflammatory urologic diseases. Urol. Nefrol. (Mosk.), 14-17 (in Russian).
37. Quinn P.J., Carter M.E., Markey B., and Carter G.R. Clinical Veterinary Microbiology (1994), Wolfe Publishing
38. Raettig, H., 1958, Bakteriophagie, 1917-1956; Zugleich ein Vorschlag zur Dokumentation wissenschaftlicher Literatur. Gustav Fischer Verlag, Stuttgart (in German).
39. Reynaud A., Cloastre L., Bernard J., Laveran H., Ackermann H.W., Licois D., and Joly B. Characteristics and diffusion in the rabbit of a phage for Escherichia coli 0103. Attempts to use this phage for therapy. Vet. Microbiol. 30 (1992) 203-212
40. Russo T.A., and Johnson J.R. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect. 5 (2003) 449-456
41. Sambrook J., and Russell D.W. Molecular Cloning. third ed. (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
42. Schilling J.D., Lorenz R.G., and Hultgren S.J. Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect. Immun. 70 (2002) 7042-7049
43. Seguin M.A., Vaden S.L., Altier C., Stone E., and Levine J.F. Persistent urinary tract infections and reinfections in 100 dogs (1989-1999). J. Vet. Intern. Med. 17 (2003) 622-631
44. Slopek S., Weber-Dabrowska B., Dabrowski M., and Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch. Immunol. Ther. Exp. (Warsz.) 35 (1987) 569-583
45. Smith H.W., and Huggins M.B. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128 (1982) 307-318
46. Smith H.W., and Huggins M.B. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol. 129 Pt 8 (1983) 2659-2675
47. *and other Methods) (Sunderland, Massachusetts, Sinauer Associates).
48. Tetart F., Desplats C., and Krisch H.M. Genome plasticity in the distal tail fiber locus of the T-even bacteriophage: recombination between conserved motifs swaps adhesin specificity. J. Mol. Biol. 282 (1998) 543-556
49. Tetart F., Desplats C., Kutateladze M., Monod C., Ackermann H.W., and Krisch H.M. Phylogeny of the major head and tail genes of the wide-ranging T4-type bacteriophages. J. Bacteriol. 183 (2001) 358-366
50. Wagner P.L., and Waldor M.K. Bacteriophage control of bacterial virulence. Infect. Immun. 70 (2002) 3985-3993
51. Weber-Dabrowska B., Dabrowski M., and Slopek S. Studies on bacteriophage penetration in patients subjected to phage therapy. Arch. Immunol. Ther. Exp. (Warsz.) 35 (1987) 563-568
52. Weber-Dabrowska B., Mulczyk M., and Gorski A. Bacteriophage therapy of bacterial infections: an update of our institute's experience. Arch. Immunol. Ther. Exp. (Warsz.) 48 (2000) 547-551
53. Whittam T.S., Wolfe M.L., and Wilson R.A. Genetic relationships among Escherichia coli isolates causing urinary tract infections in humans and animals. Epidemiol. Infect. 102 (1989) 37-46